Curr Opin Cell Biol 16(5): 558-564

Regulation of matrix biology by matrix metalloproteinases

^{Department of Anatomy and Comprehensive Cancer Center, University of California, San Francisco, CA 9414-0452, USA}

^{Corresponding author: Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA,}vog.lbl@ttoMDJ

Abstract

Matrix metalloproteinases (MMPs) are endopeptidases that contribute to growth, development and wound healing as well as to pathologies such as arthritis and cancer. Until recently, it has been thought that MMPs participate in these processes simply by degrading extracellular matrix (ECM) molecules. However, it is now clear that MMP activity is much more directed and causes the release of cryptic information from the ECM. By precisely cleaving large insoluble ECM components and ECM-associated molecules, MMPs liberate bioactive fragments and growth factors and change ECM architecture, all of which influence cellular behavior. Thus, MMPs have become a focal point for understanding matrix biology.

Abstract

Footnotes

This review comes from a themed issue on Cell-to-cell contact and extracellular matrix Edited by Kathleen Green and Fiona Watt

Footnotes

References and recommended reading

References

1. Miranti CK, Brugge JSSensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002;4:83–90.[PubMed][Google Scholar]
2. Michele DE, Campbell KDystrophin–glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem. 2003;278:15457–15460.[PubMed][Google Scholar]
3. Yoneda A, Couchman JRRegulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 2003;22:25–33.[PubMed][Google Scholar]
4. Hynes ROIntegrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687.[PubMed][Google Scholar]
5. McCawley LJ, Matrisian LMMatrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534–540.[PubMed][Google Scholar]
6. Schenk S, Quaranta VTales from the cryptic sites of the extracellular matrix. Trends Cell Biol. 2003;13:366–375. This is a comprehensive review describing cryptic bioactive fragments from ECM proteins. [[PubMed][Google Scholar]
7. Ortega N, Werb ZNew functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci. 2002;115:4201–4214.[Google Scholar]
8. Sternlicht MD, Werb ZHow matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.[Google Scholar]
9. Martignetti JA, Al Aqeel A, Al Sewairi W, Boumah CE, Kambouris M, Al Mayouf S, Sheth KV, Al Eid W, Dowling O, Harris J, et al Mutation of the matrix metalloproteinase 2 gene (MMP-2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet. 2001;28:261–264.[PubMed][Google Scholar]
10. Vu THDon’t mess with the matrix. Nat Genet. 2001;28:202–203.[PubMed][Google Scholar]
11. Hangai M, Kitaya N, Xu J, Chan CK, Kim JJ, Werb Z, Ryan SJ, Brooks PCMatrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol. 2002;161:1429–1437.[Google Scholar]
12. Xu J, Rodriguez D, Peticlerc E, Kim JJ, Hangai M, Yuen SM, Davis GE, Brooks PCProteolytic exposure of a cryptic site within collagen Type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069–1079.[Google Scholar]
13. Kalluri RBasement membranes: structure, assembly and role in tumor angiogenesis. Nat Rev Cancer. 2003;3:422–433.[PubMed][Google Scholar]
14. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri RPhysiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell. 2003;3:589–601. This is an in vivo study showing that tumstatin is a physiologically functional angiogenesis inhibitor that is released from collagen IV by MMP-9 cleavage. [Google Scholar]
15. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RVEndorepellin, a novel inhibitor of angiogenesis derived from the C terminus of Perlecan. J Biol Chem. 2003;278:4238–4249.[PubMed][Google Scholar]
16. Gilles C, Polette M, Coraux C, Tournier J-M, Meneguzzi G, Munaut C, Volders L, Rouselle P, Birembaut P, Foidart J-MContribution of MT1-MMP and of human laminin-5 γ2 chain degradation to mammary epithelial cell migration. J Cell Sci. 2001;114:2967–2976.[Google Scholar]
17. Koshikawa N, Giannelli G, Cirulli V, Migyazaki K, Quaranta VRole of cell surface metalloproteinase MT1-MMP in epithelial cell migration over Laminin-5. J Cell Biol. 2000;148:615–625.[Google Scholar]
18. Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, Quaranta VBinding to EGF receptor of a Laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol. 2003;161:197–209.[Google Scholar]
19. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole RA, Pidoux I, et al MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999;99:81–92.[PubMed][Google Scholar]
20. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, Quaranta VProteolytic processing of taminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J. 2004;18:364–366.[PubMed][Google Scholar]
21. Pirila E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi PMatrix metalloproteinases process the laminin-5 γ2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003;303:1012–1017. This study identifies the sites in laminin-5 that are cleaved by MMPs and shows that the specificity of the cleavage site is important for bioactivity of the cryptic laminin-5 fragment. [[PubMed][Google Scholar]
22. Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, Motegi K, Vojtesek B, Kankova K, Furrie E, et al Migration-stimulating factor: a genetically truncated oncofetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res. 2003;63:8827–8836.[PubMed][Google Scholar]
23. Park JE, Keller GA, Ferrara NThe vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317–1326.[Google Scholar]
24. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al Matrix metalloproteinase 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–744.[Google Scholar]
25. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi RMatrix metalloproteinases (MMP-9 and MMP-2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003;63:5224–5229.[PubMed][Google Scholar]
26. Annes JP, Munger JS, Rifkin DBMaking sense of latent TGFβ activation. J Cell Sci. 2003;116:217–224.[PubMed][Google Scholar]
27. Yu Q, Stamenkovic ICell-surface-localized matrix metalloproteinase 9 proteolytically activates TGFβ and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163–176.[Google Scholar]
28. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SLThe integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGFβ1. J Cell Biol. 2002;157:493–507.[Google Scholar]
29. Dangelo M, Sarment DP, Billings PC, Pacifici MActivation of transforming growth factor β in chondrocytes undergoing endochondral ossification. J Bone Miner Res. 2001;16:2339–2347.[PubMed][Google Scholar]
30. Dallas SL, Rosser JL, Mundy GR, Bonewald LFProteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. J Biol Chem. 2002;277:21352–21360. This work identifies LTBP as a novel substrate for MMPs and show that proteolysis may be the first step in the activation of growth factors sequestered in the ECM. [[PubMed][Google Scholar]
31. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BDThe first stage of transforming growth factor β 1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle Stromelysin-1 (MMP-3) Calcif Tissue Int. 2002;70:54–65.[PubMed][Google Scholar]
32. Neptune E, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HCDysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407–411. This work shows that matrix sequestration of cytokines is a critical point for the regulation of their activity. [[PubMed][Google Scholar]
33. Abreu JG, Coffinier C, Larrain J, Oelgeschlager M, DeRobertis EMChordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene. 2002;287:39–47.[PubMed][Google Scholar]
34. Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura KProcessing of β-dystroglycan by matrix metalloproteinases disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet. 2001;10:1563–1569.[PubMed][Google Scholar]
35. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield MShedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a timp-3 sensitive metalloproteinase. J Cell Biol. 2000;148:811–824.[Google Scholar]
36. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato HCleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003;278:40764–40770.[PubMed][Google Scholar]
37. Liu BY, Kim YC, Leatherberry V, Cowin P, Alexander CMMammary gland development requires syndecan-1 to create a β-catenin/TCF-responsive mammary epithelial subpopulation. Oncogene. 2003;22:9243–9253.[PubMed][Google Scholar]
38. Liu BY, McDermott SP, Khwaja SS, Alexander CMThe transforming activity of wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci USA. 2004;101:4158–4163.[Google Scholar]
39. Beare AH, O’Kane S, Krane SM, Ferguson MWSeverely impaired wound healing in the collagenase-resistant mouse. J Invest Dermatol. 2003;120:153–163.[PubMed][Google Scholar]
40. Chiusaroli R, Maier A, Knight MC, Byrne M, Calvi LM, Baron R, Krane SM, Schipani ECollagenase cleavage of type I collagen is essential for both basal and parathyroid hormone (PTH) PTH-related peptide receptor-induced osteoclast activation and has differential effects on discrete bone compartments. Endocrinology. 2003;144:4106–4116.[PubMed][Google Scholar]
41. Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RTEffect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res. 2003;93:238–245.[PubMed][Google Scholar]
42. Stanton H, Fosang AJMatrix metalloproteinases are active following guanidine hydrochloride extraction of cartilage: generation of DIPEN neoepitope during dialysis. Matrix Biol. 2002;21:425–428.[PubMed][Google Scholar]
43. Chu Q, Lopez M, Hayashi K, Ionescu M, Billinghurst RC, Johnson KA, Poole RA, Markel MDElevation of collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage. 2002;10:662–669.[Google Scholar]
44. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole RARelationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 2001;44:2503–2511.[PubMed][Google Scholar]
45. Fosang AJ, Last K, Jackson DC, Brown LAntibodies to MMP-cleaved aggrecan. Methods Mol Biol. 2001;151:425–449.[PubMed][Google Scholar]
46. Strazynski M, Eble JA, Kresse H, Schonherr EInterleukin (IL)-6 and IL-10 induce DEcoRIn mRNA in endothelial cells, but interaction with fibrillar collagen is essential for its translation. J Biol Chem. 2004;279:21266–21270.[PubMed][Google Scholar]
47. Coloradao PC, Torre A, Kamphaus G, Maeshima Y, Hopfter H, Takahashi K, Volk R, Amborsky ED, Herman S, Sarkar PK, et al Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000;60:2520–2526.[PubMed][Google Scholar]
48. Kamphaus GD, Coloradao PC, Panka DJ, Hopfter H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri RCanstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000;275:1209–1215.[PubMed][Google Scholar]
49. Peticlerc E, Boutaud A, Prestayko A, Xu J, Yoshikazu S, Ninomiya Y, Maichael P, Sarras J, Hudson BG, Brooks PCNew functions for non-collagenous domains of human collagen type IV. J Biol Chem. 2000;275:8051–8061.[PubMed][Google Scholar]
50. Maeshima Y, Colorado PC, Kalluri RTwo RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 2000;275:23745–23750.[PubMed][Google Scholar]
51. Xu R, Yao ZY, Xin L, Zhang Q, Li TP, Gan RBNC1 domain of human type VIII collagen (α 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Commun. 2001;289:264–268.[PubMed][Google Scholar]
52. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VPAntiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999;255:735–739.[PubMed][Google Scholar]
53. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman JEndostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285.[PubMed][Google Scholar]
54. Davis GE, Bayless KJ, Davis MJ, Meininger GARegulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol. 2000;156:1489–1498.[Google Scholar]
55. Schor SL, Schor AMTumour-stromal interactions: phenotypic and genetic alterations in mammary stroma — implications for tumour progression. Breast Cancer Res. 2001;3:373–379.[Google Scholar]